Roberto Dominici1, Dario Finazzi2,3, Letizia Polito4, Emanuela Oldoni5, Giovanna Bugari2, Alessandro Montanelli2, Elio Scarpini5, Daniela Galimberti5, Antonio Guaita4. 1. a ASST Ovest Milanese Laboratory of Clinical Chemistry, Magenta Hospital , Legnano , Italy. 2. b Department of Molecular and Translational Medicine , University of Brescia , Brescia , Italy. 3. c Clinical Chemistry Laboratory, Diagnostic Department , ASST Spedali Civili di Brescia , Brescia , Italy. 4. d Fondazione Golgi-Cenci Abbiategrasso (MI) , Milano , Italy. 5. e Neurodegenerative Disease Unit, Department of Pathophysiology and Transplantation , "Dino Ferrari" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico , Milan , Italy.
Abstract
BACKGROUND: Several studies performed in the last years on the brain, showed that beta2-microglobulin (β2m) and MHC can act independently of their canonical immune function to regulate normal brain development, synaptic plasticity and behaviour. Increased systemic levels of soluble β2m have been implicated in cognitive impairments like that associated with chronic haemodialysis, or aortic valve replacement. Increased soluble β2m has also been detected in the cerebral spinal fluid (CSF) of patients with HIV-associated dementia and Alzheimer's disease (AD). OBJECTIVE: To compare plasma β2m levels in healthy subjects and subjects with dementia or cognitive impairment. METHODS: We measured the concentration of β2m in a cohort of 245 individuals and compared sex matched, cognitive healthy individuals. RESULTS: We found higher levels of β2m in AD patients compared to non-AD MCI and healthy controls (2063 ng/mL ±852 versus 1613 ± 503 and 1832 ± 382 ng/mL, p< 0.001 and <0.033, respectively), while there was no difference between mild cognitive impairment (MCI) and healthy controls (p > 0.05). CONCLUSIONS: Our data confirm that β2m could play a role in AD. However, a replication study in an independent cohort would be necessary to confirm our preliminary results.
BACKGROUND: Several studies performed in the last years on the brain, showed that beta2-microglobulin (β2m) and MHC can act independently of their canonical immune function to regulate normal brain development, synaptic plasticity and behaviour. Increased systemic levels of soluble β2m have been implicated in cognitive impairments like that associated with chronic haemodialysis, or aortic valve replacement. Increased soluble β2m has also been detected in the cerebral spinal fluid (CSF) of patients with HIV-associated dementia and Alzheimer's disease (AD). OBJECTIVE: To compare plasma β2m levels in healthy subjects and subjects with dementia or cognitive impairment. METHODS: We measured the concentration of β2m in a cohort of 245 individuals and compared sex matched, cognitive healthy individuals. RESULTS: We found higher levels of β2m in ADpatients compared to non-AD MCI and healthy controls (2063 ng/mL ±852 versus 1613 ± 503 and 1832 ± 382 ng/mL, p< 0.001 and <0.033, respectively), while there was no difference between mild cognitive impairment (MCI) and healthy controls (p > 0.05). CONCLUSIONS: Our data confirm that β2m could play a role in AD. However, a replication study in an independent cohort would be necessary to confirm our preliminary results.
Authors: Johannes B Scheppach; Josef Coresh; Aozhou Wu; Rebecca F Gottesman; Thomas H Mosley; David S Knopman; Morgan E Grams; A Richey Sharrett; Silvia Koton Journal: Am J Kidney Dis Date: 2020-05-16 Impact factor: 8.860
Authors: Scott B Laffoon; James D Doecke; Anne M Roberts; Jennifer A Vance; Benjamin D Reeves; Kelly K Pertile; Rebecca L Rumble; Chris J Fowler; Brett Trounson; David Ames; Ralph Martins; Ashley I Bush; Colin L Masters; Paul A Grieco; Edward A Dratz; Blaine R Roberts Journal: Proteome Sci Date: 2022-01-26 Impact factor: 2.480